Novel Therapies for the Treatment of MS

Slides:

Advertisements

Similar presentations

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Advertisements

NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: Results from the OPERA I and OPERA II, phase III studies G.

Multiple sclerosis: Oral Therapies and Beyond

Novel Regimens and Considerations in Radionuclide Therapy for mCRPC

Immune Depletion, Immune Modulation, and Immunosuppression in MS: A Review.

Highlights From the 2015 European Multiple Sclerosis Meeting

NOACs for Cancer-Associated Thrombosis:

LDL Established Target for Cardiovascular Risk

Perspectives on Key MS Data From the Annual European MS Meeting

MS Highlights From the 2017 Annual Neurology Meeting

Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

A CASE CHALLENGE IN HFrEF:

Discussion Outline Cells of the Immune System.

What Predicts Disability Progression in Multiple Sclerosis?

Current Controversies in Multiple Sclerosis Management

From Conference to the Clinic

PAD Patients vs Post-ACS Patients:

Renal and Extrarenal Complications of ADPKD: Facilitating Better Patient Care.

Progressive Fibrosing Interstitial Lung Diseases – Addressing the Challenges Concept of Progressive Fibrosing ILDs With Examples.

Perspectives on Key MS Data From the Annual Neurology Meeting

Cancer Stem Cell Therapies in Gastrointestinal Cancers

Select Topics in Cardiovascular Medicine

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

T-Cell Directed Therapy in MS

New Treatments for CTEPH

Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

Optimizing Patient Outcomes in IBD

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

When Would You Use Single Inhaler Triple Therapy in COPD?

Assessing Disease Progression in MS Treatment

Improving Risk Assessment and Early Diagnosis in PAH

Selected Highlights of the Latest Advances in PAH

Is RA Treatment Addressing the Real Needs of Patients?

Updates on Anti-VEGF Therapy: Improving Durability and Predicting Response.

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Charting Progress in MS Treatment:

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

Radical New Concepts in Lipid Management

Advancing the Treatment of IBD With Biologics

Treating to Target in MS

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Novel Approaches to T1D Management

Improving Outcomes in Psoriatic Arthritis

Physiology Myocardial Oxygen Supply and Demanda,b.

Intro: Biomarkers in RA

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

The Road to Quality Improvement in HER2-Positive Breast Cancer

CMV in the HSCT Recipient

Implications of Emerging Treatments for Beta-Thalassemia

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Are We Making Progress in the Management of Huntington Disease?

Reducing Risk for CV Outcomes

Emerging Multiple Sclerosis Therapies

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

A Family Affair.

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Novel Therapeutics in MS

Third-Generation EGFR TKIs

Targeting Apoptosis in AML

Evaluating Success of Current Treatments for HCM

Clinical Comparisons in CTEPH

Updates in Progressive MS

Understanding the Role of Disability in MS Management

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

You Don't Know JAK in IBD.

Translating Data From Trial to Practice

Presentation transcript:

Novel Therapies for the Treatment of MS

Daclizumab: Mechanism of Action

SELECT: Study Results

DECIDE: Study Design

DECIDE: Study Results

DECIDE: Safety Data

DAC HYP: Safety

Mechanism of Action of B-Cell-Targeted Therapy in MS

OPERA I and II: Study Designs

OPERA I and OPERA II: Pooled Data Analysis

OPERA I and II: Study Results at 96 Weeks

OPERA I and II: Relative Reduction in MRI Measures With Ocrelizumab as Compared With IFN-β1a

OPERA I and II: Safety

ORATORIO: Study Design

ORATORIO: Risk of Disease Progression

ORATORIO: Safety

INFORMS: Study Design and Results

INFORMS: Impact of Baseline NBV on Likelihood of Disease Progression

S1P1 Modulators

ASCEND: Study Design

ASCEND: Study Results

Proposed Anti-LINGO MOA

RENEW: MF-VEP Substudy Results*

SYNERGY: Trial Design and Results

MS-SPI: Trial Design

MS-SPI: Subgroup Analyses

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)